Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.

The highly selective agonists of the A(3) adenosine receptor (AR), Cl-IB-MECA (2-chloro-N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine), and its 4'-thio analogue, were successfully converted into selective antagonists simply by appending a second N-methyl group on the 5'-uronamide position. The 2-chloro-5'-(N,N-dimethyl)uronamido analogues bound to, but did not activate, the human A(3)AR, with K(i) values of 29 nM (4'-O) and 15 nM (4'-S), showing >100-fold selectivity over A(1), A(2A), and A(2B)ARs. Competitive antagonism was demonstrated by Schild analysis. The 2-(dimethylamino)-5'-(N,N-dimethyl)uronamido substitution also retained A(3)AR selectivity but lowered affinity.

[1]  K. Jacobson,et al.  The Cross-Species A3 Adenosine-Receptor Antagonist MRS 1292 Inhibits Adenosine-Triggered Human Nonpigmented Ciliary Epithelial Cell Fluid Release and Reduces Mouse Intraocular Pressure , 2005, Current eye research.

[2]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.

[3]  K. Jacobson,et al.  N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. , 2003, Biochemical pharmacology.

[4]  Kenneth A. Jacobson,et al.  Structural Determinants of A3 Adenosine Receptor Activation: Nucleoside Ligands at the Agonist/Antagonist Boundary , 2002 .

[5]  Kenneth A Jacobson,et al.  Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. , 2003, Journal of medicinal chemistry.

[6]  K. Jacobson,et al.  Purine receptors: GPCR structure and agonist design. , 2004, Molecular interventions.

[7]  B. Fredholm,et al.  Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.

[8]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[9]  K. Jacobson,et al.  N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. , 2003, Journal of medicinal chemistry.

[10]  A. IJzerman,et al.  2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor. , 2002, Journal of medicinal chemistry.

[11]  K. Jacobson,et al.  Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. , 1996, Journal of medicinal chemistry.

[12]  Y. Kurogi,et al.  Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. , 2004, Bioorganic & medicinal chemistry letters.

[13]  K. Jacobson,et al.  RADIOLABELING AND EFFICIENT SYNTHESIS OF TRITIATED 2-CHLORO-N6-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURON-AMIDE, A POTENT, SELECTIVE A3 ADENOSINE RECEPTOR AGONIST. , 1996, Journal of labelled compounds & radiopharmaceuticals.

[14]  S. Moro,et al.  Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. , 2002, Journal of medicinal chemistry.

[15]  K. Jacobson,et al.  (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. , 2005, Journal of medicinal chemistry.

[16]  A. IJzerman,et al.  A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds. , 1998, Journal of medicinal chemistry.

[17]  Barbara Cacciari,et al.  Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.

[18]  K. Jacobson,et al.  Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety. , 2004, Biochemical pharmacology.